Cellulitis caused by Capnocytophaga cynodegmi associated with etanercept treatment in a patient with rheumatoid arthritis.
J C
JC
Gerster
J
J
Dudler
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001733:Bites and Stings / Q000150:complications; D002206:Capnocytophaga; D002415:Cats; D002481:Cellulitis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000382:microbiology; D017291:Clarithromycin / Q000627:therapeutic use; D000068800:Etanercept; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000209:etiology*; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000009:adverse effects*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D017291:Clarithromycin; D000068800:Etanercept